论文部分内容阅读
上皮性卵巢癌是目前危害妇女健康的常见恶性肿瘤之一。由于其具起病隐匿、易于早期在腹腔内播散、转移的临床特征,因而在卵巢癌初诊病人中70%已为中、晚期患者,其治疗效果差、预后不良。上皮性卵巢癌的治疗目前仍遵循手术-化疗-化疗的辅助治疗这一基本模式,但远期疗效尚无重大改善,其5年生存率仍徘徊在30%左右。新辅助化疗(Neoadjurant chemotherapy)是近年在癌症治疗中提出的新概念,亦是近10年来在上皮性卵巢癌治疗方面兴起的治疗手段。即在明确恶性肿瘤诊断的基础上,选择有效的化疗药物,给予病人有限的疗程化疗后,再行最大限度的肿瘤
Epithelial ovarian cancer is one of the common malignant tumors that endanger women’s health. Because of its occult onset, easy early in the abdominal cavity disseminated, the clinical features of metastasis, and thus newly diagnosed ovarian cancer patients in 70% of patients with advanced, the treatment effect is poor, the prognosis is poor. Epithelial ovarian cancer treatment is still follow the basic pattern of adjuvant chemotherapy - chemotherapy - chemotherapy, but there is no significant long-term improvement in the efficacy of its 5-year survival rate still hovering around 30%. Neoadjurant chemotherapy is a new concept put forward in the treatment of cancer in recent years and is also a treatment method that has emerged in the treatment of epithelial ovarian cancer in the past 10 years. That is clear on the basis of the diagnosis of malignant tumors, the choice of effective chemotherapy drugs, given the patient a limited course of chemotherapy, and then the maximum tumor